Increasing Leqembi® royalties and new partnership with Novartis STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- Events during the second quarter 2025 The European Commission granted Marketing Authorisation (MA) for Leqembi® (lecanemab), triggering a milestone payment of EUR 20 M from Eisai The...
Hence then, the article about bioarctic interim report for the period april june 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic: Interim Report for the period April - June 2025 )
Also on site :
- Human heads displayed at Ecuador tourist beach in warning to gangs
- Nazi salutes and drug cartels: Dutch mercenary recounts service with Kiev’s military
- Retailers Help Mitigate Risk with Oracle's AI-Driven Supply Chain Collaboration